May 3, 2024
Indivior PLC (the
'Company')
Publication of Circular and
Notice of General Meeting
On April 25, 2024, the Board of
Directors of the Company confirmed its intention, following
extensive consultation with shareholders, to seek shareholder
approval in May 2024 to effect a primary listing in the U.S., while
maintaining a secondary listing in the U.K.. In order to effect a
primary listing in the U.S., shareholder approval is being sought
to transfer the Company's listing category on the Official List of
the U.K. Financial Conduct Authority ("FCA") from a Premium Listing
(commercial company) to a Standard Listing (shares) (the
"Proposed
Transfer").
Further to that announcement, the
Company has today posted or made available to shareholders a
circular (the "Circular")
incorporating a notice of general meeting (the "General Meeting") regarding the
Proposed Transfer.
Copies of the following documents
have been submitted to the FCA and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:
- Circular incorporating the notice of General Meeting;
and
- Form
of Proxy for the General Meeting.
The Circular incorporating the
notice of General Meeting can also be viewed on the Company's
website at www.indivior.com/en/investors/shareholder-information and
will be
available for inspection at the place of the General Meeting for at
least 15 minutes before and during the General Meeting.
The General Meeting will be held on
Thursday, May 23, 2024, at 12.00 p.m. (U.K. time) at the offices of
Freshfields Bruckhaus Deringer LLP, 100
Bishopsgate, London EC2P 2SR.
The expected timetable for the
General Meeting and the Proposed Transfer is set out below. All
times shown in this timetable are U.K. time.
Event
|
|
Expected
time/date
|
Record date for DTC beneficial owners to be eligible to
vote
|
|
Friday, May 10, 2024
|
Latest time
and date for receipt of Forms of Direction
(U.K. CSN holders)
|
|
12.00p.m. on
Friday, May 17, 2024
|
Record date
for CSN holders to be eligible to vote
|
|
6.00p.m.
on
Friday, May 17, 2024
|
Record date
for U.K. Depositary Interest holders to be eligible to
vote
|
|
6.00p.m.
on
Friday, May 17, 2024
|
Latest time
and date for receipt of Forms of Instruction
(U.K. Depositary Interest holders)
|
|
12.00p.m. on
Monday, May 20, 2024
|
Latest time
and date for receipt of Forms of Proxy
(direct shareholders)
|
|
12.00p.m.
on Tuesday, May 21, 2024
|
Record date
for direct shareholders to attend and vote
at the General Meeting
|
|
12.00p.m.
on
Tuesday, May 21, 2024
|
General
Meeting
|
|
12.00p.m.
on
Thursday, May 23, 2024
|
Proposed
Transfer becomes effective and trading of Indivior Shares commences
as a Standard Listing company
|
|
8.00a.m.
on
Thursday, June 27, 2024
|
All dates are based on Indivior's
current expectations and may be subject to change. If any of the
times or dates change, Indivior will give notice of the change by
issuing an announcement through a Regulatory Information
Service.
Capitalised terms used but not
otherwise defined in this announcement have the same meaning given
to them in the Circular.
Key
Contacts:
Jason Thompson
VP, Investor Relations
+1 804-402-7123
or jason.thompson@indivior.com
Tim Owens
Director, Investor
Relations
+1 804-263-3978
or timothy.owens@indivior.com
Kathryn Hudson
Company Secretary
+44 (0)1753 423940
or kathryn.hudson@indivior.com
Indivior PLC's Legal Entity
Identifier code is 213800V3NCQTY7IED471.
About Indivior
Indivior is a global pharmaceutical
company working to help change patients' lives by developing
medicines to treat substance use disorders (SUD) and serious mental
illnesses. Our vision is that all patients around the world will
have access to evidence-based treatment for the chronic conditions
and co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD,
including alcohol use disorder and cannabis use disorder.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,100 individuals globally and its portfolio of
products is available in 37 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/
company/indivior.